- Prev close
- 1,175
- Volume (shares)
- 1,195,618
- Data time
- 2026-10-22 13:30:00
- Open
- 1,195.00
- High
- 1,195.00
- Low
- 1,160.00
- Prev close
- 1,175.00
- Volume (lots)
- 1,196
- Turnover
- 14 億
- P/E
- 56.8
- Cash yield
- 0.22%
Related news
- 〈焦點股〉藥華藥Ropeg持續報捷獲中國ET藥證 漲逾半根停板
鉅亨網 · 10/16 11:06
- 藥華藥:本公司新藥BESREMi（Ropeginterferon alfa-2b）獲中國國家藥品監督管理局（NMPA）核准使用於治療成人原發性血小板增多症（ET）
鉅亨網 · 10/15 18:11
- 藥華藥:本公司代子公司PharmaEssentia Singapore Pte. Ltd.公告向新加坡衛生科學局申請新藥BESREMi新增適應症，新增適應症為原發性血小板過多症（ET）
鉅亨網 · 10/12 21:01
- 鉅亨速報 - Factset 最新調查：藥華藥(6446-TW)EPS預估上修至27.06元，預估目標價為1600元
鉅亨網 · 10/12 08:11
- 藥華藥(6446)前三季營收197億！美、日核准ET超預期，正式啟動PV+ET雙適應症時代
鉅亨網 · 10/06 16:00
- 藥華藥PV及ET雙引擎持續發威 9月營收年增1倍續創單月高
鉅亨網 · 10/06 10:37
- 藥華藥9月營收26.35億元年增99.98% 1—9月達197.37億元
鉅亨網 · 10/06 09:46
- 營收速報 - 藥華藥(6446)9月營收26.35億元年增率高達99.98％
鉅亨網 · 10/06 08:20
- 藥華藥完成收購予宇生技股權交割 強化RNA藥物與體內CAR-T技術布局
鉅亨網 · 09/29 09:37
- 鉅亨速報 - Factset 最新調查：藥華藥(6446-TW)EPS預估上修至26.63元，預估目標價為1586元
鉅亨網 · 09/24 12:10
Company announcements
Loading…
Announcements are filed by the company; the MOPS original prevails.
tenmz is an investment education and personal analysis tool. It is not a licensed securities investment consulting enterprise in Taiwan and does not recommend any security or provide buy or sell advice. Data is for learning and reference only and may be delayed, incomplete or inaccurate; official announcements by the Taiwan Stock Exchange, the Taipei Exchange and the Market Observation Post System prevail. You are solely responsible for your own investment decisions. Investing involves risk, including the loss of principal. In case of any discrepancy, the Chinese version of these terms prevails.